BRAF V600E 突变转移性黑色素瘤中的线粒体功能障碍与免疫抑制 - Suppr

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

作者信息

Pinto de Almeida Natália, Jánosi Ágnes Judit, Hong Runyu, Rajeh Ahmad, Nogueira Fábio, Szadai Leticia, Szeitz Beata, Pla Parada Indira, Doma Viktória, Woldmar Nicole, Guedes Jéssica, Újfaludi Zsuzsanna, Bartha Aron, Kim Yonghyo, Welinder Charlotte, Baldetorp Bo, Kemény Lajos Vince, Pahi Zoltan, Wan Guihong, Nguyen Nga, Pankotai Tibor, Győrffy Balázs, Pawłowski Krzysztof, Horvatovich Peter, Szasz Attila Marcell, Sanchez Aniel, Kuras Magdalena, Rodriguez Murillo Jimmy, Betancourt Lazaro, Domont Gilberto B, Semenov Yevgeniy R, Yu Kun-Hsing, Kwon Ho Jeong, Németh István Balázs, Fenyő David, Wieslander Elisabet, Marko-Varga György, Gil Jeovanis

机构信息

Laboratory of Proteomics/LADETEC, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.

Proteomics Unit, Institute of Chemistry, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Clin Transl Med. 2024 Jul;14(7):e1773. doi: 10.1002/ctm2.1773.

DOI:10.1002/ctm2.1773

PMID:39032005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11259597/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/282e/11259597/df1370cd4f87/CTM2-14-e1773-g004.jpg

相似文献

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

Clin Transl Med. 2024 Jul;14(7):e1773. doi: 10.1002/ctm2.1773.

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.

Cancer Res. 2014 Dec 15;74(24):7298-308. doi: 10.1158/0008-5472.CAN-14-1339. Epub 2014 Oct 28.

Analysis of BRAF mutation in primary and metastatic melanoma.

Cell Cycle. 2005 Oct;4(10):1382-4. doi: 10.4161/cc.4.10.2026. Epub 2005 Oct 13.

Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in Mutant Melanoma.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma.

Sci Rep. 2025 Jul 14;15(1):25430. doi: 10.1038/s41598-025-11054-2.

Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.

J Invest Dermatol. 2013 May;133(5):1378-81. doi: 10.1038/jid.2012.485. Epub 2013 Jan 10.

BRAF V600E-dependent role of autophagy in uveal melanoma.

J Cancer Res Clin Oncol. 2017 Mar;143(3):447-455. doi: 10.1007/s00432-016-2317-y. Epub 2016 Dec 7.

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.

Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

Exp Mol Pathol. 2014 Dec;97(3):315-20. doi: 10.1016/j.yexmp.2014.09.008. Epub 2014 Sep 16.

Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.

Oncol Rep. 2014 Aug;32(2):808-14. doi: 10.3892/or.2014.3265. Epub 2014 Jun 13.

引用本文的文献

Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.

J Clin Med. 2025 Jun 12;14(12):4193. doi: 10.3390/jcm14124193.

Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.

Cancer. 2025 Jul 1;131(13):e35897. doi: 10.1002/cncr.35897.

本文引用的文献

Protein neddylation and its role in health and diseases.

Signal Transduct Target Ther. 2024 Apr 5;9(1):85. doi: 10.1038/s41392-024-01800-9.

Mitochondrial and immune response dysregulation in melanoma recurrence.

Clin Transl Med. 2023 Nov;13(11):e1495. doi: 10.1002/ctm2.1495.

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Cancers (Basel). 2023 Aug 8;15(16):4026. doi: 10.3390/cancers15164026.

Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression.

Nat Commun. 2022 Jul 6;13(1):3882. doi: 10.1038/s41467-022-31417-x.

The Interplay between Cell-Extracellular Matrix Interaction and Mitochondria Dynamics in Cancer.

Cancers (Basel). 2022 Mar 10;14(6):1433. doi: 10.3390/cancers14061433.

An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation.

Cancers (Basel). 2021 Dec 1;13(23):6066. doi: 10.3390/cancers13236066.

The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Clin Transl Med. 2021 Jul;11(7):e451. doi: 10.1002/ctm2.451.

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

PLoS One. 2020 Mar 13;15(3):e0230136. doi: 10.1371/journal.pone.0230136. eCollection 2020.

Melanoma proteomics suggests functional differences related to mutational status.

Sci Rep. 2019 May 10;9(1):7217. doi: 10.1038/s41598-019-43512-z.

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18226-31. doi: 10.1073/pnas.1317577110. Epub 2013 Oct 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

作者信息

机构信息

Laboratory of Proteomics/LADETEC, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.

Proteomics Unit, Institute of Chemistry, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Clin Transl Med. 2024 Jul;14(7):e1773. doi: 10.1002/ctm2.1773.

DOI:10.1002/ctm2.1773

PMID:39032005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11259597/

Abstract

摘要

相似文献

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

Clin Transl Med. 2024 Jul;14(7):e1773. doi: 10.1002/ctm2.1773.

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.

Cancer Res. 2014 Dec 15;74(24):7298-308. doi: 10.1158/0008-5472.CAN-14-1339. Epub 2014 Oct 28.

Analysis of BRAF mutation in primary and metastatic melanoma.

Cell Cycle. 2005 Oct;4(10):1382-4. doi: 10.4161/cc.4.10.2026. Epub 2005 Oct 13.

Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in Mutant Melanoma.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma.

Sci Rep. 2025 Jul 14;15(1):25430. doi: 10.1038/s41598-025-11054-2.

Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.

J Invest Dermatol. 2013 May;133(5):1378-81. doi: 10.1038/jid.2012.485. Epub 2013 Jan 10.

BRAF V600E-dependent role of autophagy in uveal melanoma.

J Cancer Res Clin Oncol. 2017 Mar;143(3):447-455. doi: 10.1007/s00432-016-2317-y. Epub 2016 Dec 7.

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.

Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

Exp Mol Pathol. 2014 Dec;97(3):315-20. doi: 10.1016/j.yexmp.2014.09.008. Epub 2014 Sep 16.

Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.

Oncol Rep. 2014 Aug;32(2):808-14. doi: 10.3892/or.2014.3265. Epub 2014 Jun 13.

引用本文的文献

Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.

J Clin Med. 2025 Jun 12;14(12):4193. doi: 10.3390/jcm14124193.

Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.

Cancer. 2025 Jul 1;131(13):e35897. doi: 10.1002/cncr.35897.

本文引用的文献

Protein neddylation and its role in health and diseases.

Signal Transduct Target Ther. 2024 Apr 5;9(1):85. doi: 10.1038/s41392-024-01800-9.

Mitochondrial and immune response dysregulation in melanoma recurrence.

Clin Transl Med. 2023 Nov;13(11):e1495. doi: 10.1002/ctm2.1495.

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Cancers (Basel). 2023 Aug 8;15(16):4026. doi: 10.3390/cancers15164026.

Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression.

Nat Commun. 2022 Jul 6;13(1):3882. doi: 10.1038/s41467-022-31417-x.

The Interplay between Cell-Extracellular Matrix Interaction and Mitochondria Dynamics in Cancer.

Cancers (Basel). 2022 Mar 10;14(6):1433. doi: 10.3390/cancers14061433.

An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation.

Cancers (Basel). 2021 Dec 1;13(23):6066. doi: 10.3390/cancers13236066.

The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Clin Transl Med. 2021 Jul;11(7):e451. doi: 10.1002/ctm2.451.

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

PLoS One. 2020 Mar 13;15(3):e0230136. doi: 10.1371/journal.pone.0230136. eCollection 2020.

Melanoma proteomics suggests functional differences related to mutational status.

Sci Rep. 2019 May 10;9(1):7217. doi: 10.1038/s41598-019-43512-z.

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18226-31. doi: 10.1073/pnas.1317577110. Epub 2013 Oct 21.

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献